Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)

The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety

(2017) Yingcheng Wu et al.   INTERNATIONAL JOURNAL OF CANCER

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

(2017) Paolo A Ascierto et al.   LANCET ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence of sexual dimorphism in mammalian phenotypic traits

(2017) Natasha A. Karp et al.   Nature Communications

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses

(2016) Joshua D Wallach et al.   BMJ-British Medical Journal

Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses

(2016) Joshua D Wallach et al.   BMJ-British Medical Journal

RobotReviewer: evaluation of a system for automatically assessing bias in clinical trials

(2015) Iain J Marshall et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

(2015) Alexander M. Lesokhin et al.   Science Translational Medicine

Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

(2014) L. Min et al.   CLINICAL CANCER RESEARCH

The influence of sex and gender on the immune response

(2011) Sabine Oertelt-Prigione   AUTOIMMUNITY REVIEWS

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

B7-H1-Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses

(2010) P.-Y. Lin et al.   JOURNAL OF IMMUNOLOGY

The Xs and Y of immune responses to viral vaccines

(2010) Sabra L Klein et al.   LANCET INFECTIOUS DISEASES

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE